Regeneron nabs dosing edge with Lynozyfic's FDA approval in multiple myeloma
Via an accelerated approval, Lynozyfic is indicated to treat adult patients with relapsed or refractory multiple myeloma (r/r MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody.
Regeneron's drug joins two fellow BCMAxCD3 bispecific antibodies already at market in the US – Johnson & Johnson's (J&J) Tecvayli and Pfizer's Elrexfio.
Despite playing catch-up with its rivals, Regeneron's product offers a dosing advantage. Lynozyfic, which stimulates T-cells to recognise and destroy cancer cells, can be administered monthly after 24 weeks of therapy, depending on how well the patient responds.
Meanwhile, J&J's Tecvayli can be given every two weeks in patients who show a good response after at least six months, and Elrexfio has the same dosing interval from week 25 onward. Lynozyfic also has a fortnightly dosing schedule for patients starting from week 14.
Regeneron's Phase I/II Linker-MM1 trial (NCT03761108) with Lynozyfic demonstrated an objective response rate of 70% in 80 patients with MM. Tecvayli and Elrexfio had response rates of 63% and 56% in their respective trials, though direct comparisons are difficult to draw without a head-to-head study.
Boxed warnings are common for T-cell directing drugs, and Lynozyfic is no different. It comes with one for cytokine release syndrome (CRS) and neurologic toxicity – including immune effector cell-associated neurotoxicity syndrome – in addition to warnings and precautions for infections, neutropenia, hepatotoxicity and embryo-foetal toxicity.
It is unclear how Regeneron will challenge J&J and Pfizer in MM, who both reached the market first but have less convenient dosing options.
Justin Holko, Regeneron's senior vice-president for global oncology/haematology commercial business, told Pharmaceutical Technology: 'We don't comment on sales figures or market share, but believe Lynozyfic has the potential to provide significant benefit to multiple myeloma patients, society and the healthcare system.'
Tecvayli generated $549m in 2024 while Elrexfio secured $133m. MM is the second most common blood cancer, and revenue for these drugs is expected to skyrocket. Tecvayli, for example, is forecast to reach nearly $4.5bn in annual sales by 2031, according to GlobalData's Pharma Intelligence Center. Similar analysis predicts Lynozyfic will generate $707m in sales by that year, a lower figure primarily due to Regeneron's later market entry.
International Myeloma Foundation's interim CEO Diane Moran said: '[Lynozyfic] provides appropriate multiple myeloma patients and their care teams with a novel patient-centric treatment option that includes a dosing schedule that can be adapted based on patient response. We appreciate Regeneron's continued research to further advance treatment for this community.'
"Regeneron nabs dosing edge with Lynozyfic's FDA approval in multiple myeloma" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Wednesday's Unusual Options Activity Reveals 3 Standout Long Straddle Plays
There were 981 unusually active options in Wednesday trading. Of those, 597 were calls, and 384 were puts. Generally, I like to see over 1,000 unusually active options in a single day. It's a sign of above-average options volume. Not surprisingly, yesterday's options volume was 45.05 million, 88% of the average daily option volume. Creating a 38% 'Dividend' on SOFI Stock Using Options Delta Air Lines Shows Unusual Call Options Ahead of Earnings - Investors are Bullish on DAL Stock Covered Call Screener Results For July 9th Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! No matter. The unusual options activity, as always, provided plenty of potential trading opportunities. One particular Pfizer put had a 30-day DTE (days to expiration) that caught my attention. Out of the 37 unusually active options expiring on Aug. 8, it and two others revealed three standout long straddle plays. Pfizer (PFE) Of the 37 expiring on Aug. 8, the PFE $26 put had the highest Vol/OI ratio at 102.21. Including unusually active options expiring in seven days or more, it had the third-highest Vol/OI (Volume-to-Open-Interest) ratio behind Coinbase and I last highlighted an unusually active Pfizer option in November 2024. The Jan. 15, 2027, $27 call with a 792-day DTE looked appealing to value investors because it only needed to appreciate by 17% over 26 months to break even or make a profit. Yesterday, the Jan. 15/2027 $27 call had four trades of 10, 3, 5, and 10 contracts at prices between $1.81 and $1.99. It's been a money-loser so far, with its share price down 46 cents over the past 70 days or so—plenty of time to recover. Back to the subject at hand. Pfizer remains highly profitable, offering an attractive dividend yield. It's a definite value play that eventually will move higher. The question is when? The long straddle expects volatility to increase, pushing PFE stock significantly higher or lower. The maximum loss is $1.66 or 6.49% of its $25.56 share price. The maximum profit is unlimited above $27.66 and below $24.34. The profit probability is 40.4%. It is a reasonable risk for a potentially above-average reward. Nvidia (NVDA) Nvidia just became the first $4-trillion public company. It really shouldn't come as a surprise to most investors. CEO Jensen Huang is a brilliant leader who has his company playing in all the right sandboxes. Despite being a dominant force in AI, the chipmaker's shares are only up 21% over the past 12 months. Sure, from its April 52-week low of $86.62, its shares have nearly doubled, but investors have grown accustomed to triple-digit annual returns. Hence, its valuation is at 40 times its forward earnings per share. In May 2024, I debated which of Nvidia's and Tesla's Dec. 18/2026 call options was the better bet for an early Christmas present. Although Nvidia's call cost four times more than Tesla's, I concluded that it was the better bet for long-term gains. Fast forward to today. Accounting for the June 2024 10-for-1 stock split, yesterday's trades for the $110 call ($1,100 pre-split) ranged from $67.45 to $68.60, more than double the ask price 13 months earlier. Tesla's $230 call is up about 64% over the same period. I don't think there's any question Nvidia is still the better bet. But I digress. Nvidia had seven unusually active options yesterday. Based on the current share price, the $162.50 put makes the most sense for the long straddle. Here is the long straddle. The profit probability is 41.90%, slightly higher than Pfizer's. Again, with a maximum loss of $13.30, less than 10% of Nvidia's share price, the bet's risk is reasonable, with above-average reward. SoFi Technologies (SOFI) Conveniently, I just wrote about SoFi Technologies yesterday. It had two unusually active options. I'll go with the $20 call because it's right at the money. As I mentioned yesterday, I like SOFI stock a great deal. I have for a long time. I tend to favor disruptor stocks, but only if they can generate sustainable profits over time. SoFi appears to be on its way. I concluded that it should be a $40 stock in due time. The $20 long straddle's profit probability is 41.6%, sandwiched between Pfizer and Nvidia. For some, the $3.28 maximum loss from the net debit (16.22% of its share price), is a dealbreaker. The percentage outlay is too high. I get it. However, the big money with long straddles comes with a big move in either direction, and in that regard, SoFi has the best chance to do so. Of the three long straddles, the $20 bet has the highest IV/HV ratio at 1.60, which is defined as the Implied Volatility (IV) divided by the 30-day realized historical volatility (HV). This means it is currently more volatile than it has been in the past 30 days. In this bet, volatility is your friend. On the date of publication, Will Ashworth did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
14 hours ago
- Yahoo
Pfizer and Astellas' Xtandi improves OS as combination therapy
Pfizer and Astellas' Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC), but only as a combination therapy. First approved in 2012, the prostate cancer therapy met the secondary endpoint of OS in the Phase III EMBARK trial (NCT02319837) when combined with leuprolide, compared to placebo plus leuprolide, in patients with nmHSPC with biochemical recurrence (BCR) and high risk for metastasis. Despite this, while a favourable trend was observed, there was no statistical significance between Xtandi monotherapy and placebo or leuprolide. In the trial, patients were randomised across three arms: Xtandi plus leuprolide, placebo plus leuprolide, or Xtandi alone. This update comes two years after the companies announced the trial met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) for patients treated with Xtandi plus leuprolide versus placebo plus leuprolide. Although Pfizer and Astellas have not yet disclosed additional details about the OS data, they stated that full results will be presented at an upcoming medical meeting. They also noted that safety results were consistent with the known safety profile of Xtandi. Carolina Urologic Research Center's medical director Dr Neal Shore said: 'These data demonstrate that treatment with Xtandi can extend life for men with nmHSPC and high-risk BCR who have relapsed after initial curative-intent therapy with prostatectomy, radiation therapy or both, further validating EMBARK's metastasis-free survival (MFS) data. "While men with nmHSPC with high-risk BCR now have expanded treatment choices, these results demonstrate a clear clinical benefit, including both MFS and OS, supporting the clinical practice of initiating Xtandi for these patients.' Xtandi is currently approved in more than 80 countries, including the US, Europe and Japan. The US Food and Drug Administration (FDA) approved Xtandi for use in nmHSPC with high-risk BCR in November 2023, based on the EMBARK trial meeting its primary endpoint. The European Commission (EC) granted a label expansion for its use in the same patient population in April 2024. GlobalData predicts the prostate cancer market will be worth $22.62bn in 2030. Xtandi sales are set to start dropping due to the drug's patent expiring in 2026 in Europe and 2027 in the US. As a result, GlobalData predicts that sales of Xtandi will reach $5.59bn in 2025 and will drop to $2.24bn in 2030. The pharmaceutical industry is facing one of the most significant patent cliffs of the decade, with major companies preparing for substantial revenue losses, according to market analysts. A recent GlobalData report projects a sharp decline in the proportion of global drug sales protected by patents, with the figure expected to drop to just 4% by 2030. This compares to 12% in 2022 and 6% in 2024. GlobalData is the parent company of Clinical Trials Arena. "Pfizer and Astellas' Xtandi improves OS as combination therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Yahoo
Pfizer and Astellas' Xtandi improves OS as combination therapy
Pfizer and Astellas' Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC), but only as a combination therapy. First approved in 2012, the prostate cancer therapy met the secondary endpoint of OS in the Phase III EMBARK trial (NCT02319837) when combined with leuprolide, compared to placebo plus leuprolide, in patients with nmHSPC with biochemical recurrence (BCR) and high risk for metastasis. Despite this, while a favourable trend was observed, there was no statistical significance between Xtandi monotherapy and placebo or leuprolide. In the trial, patients were randomised across three arms: Xtandi plus leuprolide, placebo plus leuprolide, or Xtandi alone. This update comes two years after the companies announced the trial met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) for patients treated with Xtandi plus leuprolide versus placebo plus leuprolide. Although Pfizer and Astellas have not yet disclosed additional details about the OS data, they stated that full results will be presented at an upcoming medical meeting. They also noted that safety results were consistent with the known safety profile of Xtandi. Carolina Urologic Research Center's medical director Dr Neal Shore said: 'These data demonstrate that treatment with Xtandi can extend life for men with nmHSPC and high-risk BCR who have relapsed after initial curative-intent therapy with prostatectomy, radiation therapy or both, further validating EMBARK's metastasis-free survival (MFS) data. "While men with nmHSPC with high-risk BCR now have expanded treatment choices, these results demonstrate a clear clinical benefit, including both MFS and OS, supporting the clinical practice of initiating Xtandi for these patients.' Xtandi is currently approved in more than 80 countries, including the US, Europe and Japan. The US Food and Drug Administration (FDA) approved Xtandi for use in nmHSPC with high-risk BCR in November 2023, based on the EMBARK trial meeting its primary endpoint. The European Commission (EC) granted a label expansion for its use in the same patient population in April 2024. GlobalData predicts the prostate cancer market will be worth $22.62bn in 2030. Xtandi sales are set to start dropping due to the drug's patent expiring in 2026 in Europe and 2027 in the US. As a result, GlobalData predicts that sales of Xtandi will reach $5.59bn in 2025 and will drop to $2.24bn in 2030. The pharmaceutical industry is facing one of the most significant patent cliffs of the decade, with major companies preparing for substantial revenue losses, according to market analysts. A recent GlobalData report projects a sharp decline in the proportion of global drug sales protected by patents, with the figure expected to drop to just 4% by 2030. This compares to 12% in 2022 and 6% in 2024. GlobalData is the parent company of Clinical Trials Arena. "Pfizer and Astellas' Xtandi improves OS as combination therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
